Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.65 |
| ▸ | BACE1 | P56817 | 4/20 | 0.65 |
| ▸ | MMP2 | P08253 | 3/20 | 0.63 |
| ▸ | MMP9 | P14780 | 3/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.63 |
| ▸ | MMP8 | P22894 | 2/20 | 0.63 |
| ▸ | MMP13 | P45452 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.54 |
| ▸ | STAT3 | P40763 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4544307 | 0.92 | MMP2 (0.74) | GSK3BBACE1MMP2MMP9NFKB1 | |
| SCHEMBL11928819 | 0.92 | MMP2 (0.74) | GSK3BBACE1MMP2MMP9NFKB1 | |
| SCHEMBL13446382 | 0.92 | MMP2 (0.74) | GSK3BBACE1MMP2MMP9NFKB1 | |
| SCHEMBL16093015 | 0.91 | HDAC1 (0.58) | GSK3BBACE1MMP2MMP9NFKB1 | |
| SCHEMBL25229250 | 0.88 | GSK3B (0.81) | GSK3BBACE1MMP9NFKB1MMP13 | |
| SCHEMBL13358175 | 0.86 | GSK3B (0.71) | GSK3BBACE1MMP2MMP9NFKB1 | |
| SCHEMBL16884580 | 0.86 | GSK3B (0.71) | GSK3BBACE1MMP2MMP9NFKB1 | |
| SCHEMBL26397843 | 0.86 | MMP9 (0.84) | GSK3BBACE1MMP2MMP9NFKB1 | |
| SCHEMBL12291330 | 0.86 | BACE1 (0.53) | GSK3BBACE1MMP2MMP9NFKB1 | |
| SCHEMBL13358511 | 0.85 | GSK3B (0.69) | GSK3BBACE1MMP2MMP9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224205-A1 | USE OF CURCUMIN OR ITS ANALOGUES IN CANCER THERAPY UTILIZING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR | NATIONAL TAIWAN UNIVERSITY (TW) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224205-A1 | USE OF CURCUMIN OR ITS ANALOGUES IN CANCER THERAPY UTILIZING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | GSK3B 1707/4885BACE1 4634/4885MMP2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.